ERVK3-1

Across TCGA pan-cancer cohorts, ERVK3-1 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of ERVK3-1’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ERVK3-1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ERVK3-1 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

HNSC, LIHC, and THCA are the cancer types where ERVK3-1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ERVK3-1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	+0.390	<.001	11	view →
LIHC	Male	II,III,IV	+0.938	<.001	9	view →
THCA	All	All	−0.276	<.001	8	view →
KICH	All	All	−0.632	<.001	6	view →
STAD	All	II,III,IV	+0.592	<.001	6	view →
CHOL	Male	All	+1.641	<.001	5	view →
BLCA	All	III,IV	+0.472	.006	4	view →
COAD	All	All	+0.223	.005	3	view →
KIRP	All	IV	+0.517	.044	2	view →
PRAD	All	All	+0.216	.006	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

ERVK3-1–HNSC

Open the HNSC breakdown →